RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Automatic Adaptation of Basal Insulin using Sensor-augmented Pump Therapy
[EN] Background: People with insulin-dependent diabetes rely on an intensified insulin regimen. Despite several guidelines, they
are usually impractical and fall short in achieving optimal glycemic outcomes. In this work, a novel technique for automatic
adaptation of the basal insulin profile of people with diabetes on sensor-augmented pump therapy is presented.
Methods: The presented technique is based on a run-to-run control law that overcomes some of the limitations of previously
proposed methods. To prove its validity, an in silico validation was performed. Finally, the artificial intelligence technique of
case-based reasoning is proposed as a potential solution to deal with variability in basal insulin requirements.
Results: Over a period of 4 months, the proposed run-to-run control law successfully adapts the basal insulin profile of a
virtual population (10 adults, 10 adolescents, and 10 children). In particular, average percentage time in target [70, 180] mg/dl
was significantly improved over the evaluated period (first week versus last week): 70.9 ± 11.8 versus 91.1 ± 4.4 (adults), 46.5
± 11.9 versus 80.1 ± 10.9 (adolescents), 49.4 ± 12.9 versus 73.7 ± 4.1 (children). Average percentage time in hypoglycemia
(<70 mg/dl) was also significantly reduced: 9.7 ± 6.6 versus 0.9 ± 1.2 (adults), 10.5 ± 8.3 versus 0.83 ± 1.0 (adolescents),
10.9 ± 6.1 versus 3.2 ± 3.5 (children). When compared against an existing technique over the whole evaluated period, the
presented approach achieved superior results on percentage of time in hypoglycemia: 3.9 ± 2.6 versus 2.6 ± 2.2 (adults),
2.9 ± 1.9 versus 2.0 ± 1.5 (adolescents), 4.6 ± 2.8 versus 3.5 ± 2.0 (children), without increasing the percentage time in
hyperglycemia.
Conclusion: The present study shows the potential of a novel technique to effectively adjust the basal insulin profile of a
type 1 diabetes population on sensor-augmented insulin pump therapy., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project has received funding from the European Union s Horizon 2020 research and innovation program under grant agreement 689810.